Blueprint Medicines Q1 2024 GAAP EPS $1.40 Beats $(1.66) Estimate, Sales $96.116M Beat $80.434M Estimate
Blueprint Medicines Q1 2024 GAAP EPS $1.40 Beats $(1.66) Estimate, Sales $96.116M Beat $80.434M Estimate
Blueprint Medicines 2024年第一季度GAAP每股收益为1.40美元，超过预期（1.66美元），销售额为9,6116万美元，超过80.434亿美元的预期
Blueprint Medicines (NASDAQ:BPMC) reported quarterly earnings of $1.40 per share which beat the analyst consensus estimate of $(1.66) by 184.34 percent. The company reported quarterly sales of $96.116 million which beat the analyst consensus estimate of $80.434 million by 19.50 percent. This is a 51.87 percent increase over sales of $63.287 million the same period last year.
Blueprint Medicines（纳斯达克股票代码：BPMC）公布的季度收益为每股1.40美元，比分析师普遍预期的1.66美元（1.66美元）高出184.34％。该公司公布的季度销售额为9,611.6万美元，比分析师普遍预期的80.434亿美元高出19.50％。这比去年同期的6328.7万美元的销售额增长了51.87％。